• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性 HLA-G 抑制 CD94/NKG2A 的表达和功能,并在 CD56bright 和 CD56dim NK 细胞中差异调节趋化性以及细胞因子和趋化因子的分泌。

Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells.

机构信息

Laboratory of Oncology, G. Gaslini Scientific Institute, Genoa, Italy.

出版信息

Blood. 2011 Nov 24;118(22):5840-50. doi: 10.1182/blood-2011-05-352393. Epub 2011 Oct 11.

DOI:10.1182/blood-2011-05-352393
PMID:21989990
Abstract

Soluble HLA-G (sHLA-G) inhibits natural killer (NK) cell functions. Here, we investigated sHLA-G-mediated modulation of (1) chemokine receptor and NK receptor expression and function and (2) cytokine and chemokine secretion in CD56bright and CD56dim NK cells. sHLA-G-treated or untreated peripheral blood (PB) and tonsil NK cells were analyzed for chemokine receptor and NK receptor expression by flow cytometry. sHLA-G down-modulated (1) CXCR3 on PB and tonsil CD56bright and CD56dim, (2) CCR2 on PB and tonsil CD56bright, (3) CX3CR1 on PB CD56dim, (4) CXCR5 on tonsil CD56dim, and (5) CD94/NKG2A on PB and tonsil CD56brigh) and CD56dim NK cells. Such sHLA-G-mediated down-modulations were reverted by adding anti-HLA-G or anti-ILT2 mAbs. sHLA-G inhibited chemotaxis of (1) PB NK cells toward CXCL10, CXCL11, and CX3CL1 and (2) PB CD56bright NK cells toward CCL2 and CXCL10. IFN-γ secretion induced by NKp46 engagement was inhibited by NKG2A engagement in untreated but not in sHLA-G-treated NK cells. sHLA-G up-regulated secretion of (1) CCL22 in CD56bright and CD56dim and (2) CCL2, CCL8, and CXCL2-CXCL3 in CD56dim PB NK cells. Signal transduction experiments showed sHLA-G-mediated down-modulation of Stat5 phosphorylation in PB NK cells. In conclusion, our data delineated novel mechanisms of sHLA-G-mediated inhibition of NK-cell functions.

摘要

可溶性 HLA-G(sHLA-G)抑制自然杀伤(NK)细胞功能。在这里,我们研究了 sHLA-G 介导的(1)趋化因子受体和 NK 受体表达和功能以及(2)CD56bright 和 CD56dim NK 细胞中细胞因子和趋化因子分泌的调节。通过流式细胞术分析 sHLA-G 处理或未处理的外周血(PB)和扁桃体 NK 细胞的趋化因子受体和 NK 受体表达。sHLA-G 下调(1)PB 和扁桃体 CD56bright 和 CD56dim 的 CXCR3,(2)PB 和扁桃体 CD56bright 的 CCR2,(3)PB CD56dim 的 CX3CR1,(4)扁桃体 CD56dim 的 CXCR5,和(5)PB 和扁桃体 CD56bright 和 CD56dim NK 细胞的 CD94/NKG2A。这种 sHLA-G 介导的下调可以通过添加抗-HLA-G 或抗-ILT2 mAb 来逆转。sHLA-G 抑制(1)PB NK 细胞向 CXCL10、CXCL11 和 CX3CL1 的趋化作用和(2)PB CD56bright NK 细胞向 CCL2 和 CXCL10 的趋化作用。在未经处理的 NK 细胞中,NKG2A 结合抑制了 NKp46 结合诱导的 IFN-γ 分泌,但在 sHLA-G 处理的 NK 细胞中没有抑制。sHLA-G 上调(1)CD56bright 和 CD56dim 的 CCL22 和(2)CD56dim PB NK 细胞的 CCL2、CCL8 和 CXCL2-CXCL3 的分泌。信号转导实验表明,sHLA-G 介导了 PBNK 细胞中 Stat5 磷酸化的下调。总之,我们的数据描绘了 sHLA-G 介导的 NK 细胞功能抑制的新机制。

相似文献

1
Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells.可溶性 HLA-G 抑制 CD94/NKG2A 的表达和功能,并在 CD56bright 和 CD56dim NK 细胞中差异调节趋化性以及细胞因子和趋化因子的分泌。
Blood. 2011 Nov 24;118(22):5840-50. doi: 10.1182/blood-2011-05-352393. Epub 2011 Oct 11.
2
Expression patterns of lectin-like natural killer receptors, inhibitory CD94/NKG2A, and activating CD94/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells.蜕膜CD56bright自然杀伤细胞上凝集素样自然杀伤受体、抑制性CD94/NKG2A和激活性CD94/NKG2C的表达模式与外周CD56dim自然杀伤细胞上的不同。
J Reprod Immunol. 2006 Jun;70(1-2):33-42. doi: 10.1016/j.jri.2005.12.008. Epub 2006 Feb 20.
3
NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain.NKG2A/CD94 是 HLA-G 的新型免疫受体,可区分 HLA-G 重链中的氨基酸差异。
Int J Mol Sci. 2020 Jun 19;21(12):4362. doi: 10.3390/ijms21124362.
4
A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis.可溶性 HLA-G 介导免疫调节的新机制:下调 T 细胞趋化因子受体表达和损害趋化性。
PLoS One. 2010 Jul 23;5(7):e11763. doi: 10.1371/journal.pone.0011763.
5
Glycodelin-A stimulates the conversion of human peripheral blood CD16-CD56bright NK cell to a decidual NK cell-like phenotype.糖蛋白 130 刺激人外周血 CD16-CD56brightNK 细胞向蜕膜 NK 细胞样表型的转化。
Hum Reprod. 2019 Apr 1;34(4):689-701. doi: 10.1093/humrep/dey378.
6
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells.CD56bright细胞在其杀伤细胞免疫球蛋白样受体(KIR)库和细胞毒性特征方面与CD56dim自然杀伤(NK)细胞不同。
Eur J Immunol. 2001 Oct;31(10):3121-7. doi: 10.1002/1521-4141(2001010)31:10<3121::aid-immu3121>3.0.co;2-4.
7
Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.L-选择素在CD56bright和CD56dim自然杀伤细胞亚群上的差异表达及功能
J Immunol. 1998 Jul 1;161(1):400-8.
8
[Different responses of CD94/NKG2A-bright and CD94/NKG2A-dim NK cell subsets isolated from patients with multiple sclerosis to interferon-beta].[从多发性硬化症患者中分离出的CD94/NKG2A高表达和CD94/NKG2A低表达自然杀伤细胞亚群对β干扰素的不同反应]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 Jun;23(6):533-5.
9
Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.可溶性 HLA-I 介导的人 NK 细胞分泌 TGF-β1,并由此下调抗肿瘤细胞溶解活性。
Eur J Immunol. 2009 Dec;39(12):3459-68. doi: 10.1002/eji.200939728.
10
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction.可溶性 HLA I 类分子通过 FasL-Fas 相互作用,在杀伤激活型 HLA I 类受体结合后诱导 NK 细胞凋亡。
Blood. 2002 Dec 1;100(12):4098-107. doi: 10.1182/blood-2002-04-1284. Epub 2002 Jul 18.

引用本文的文献

1
Butyrate enhances CD56 NK cell-driven killing of activated T cells and modulates NK cell chromatin accessibility.丁酸盐增强CD56自然杀伤细胞驱动的活化T细胞杀伤作用,并调节自然杀伤细胞的染色质可及性。
Genes Immun. 2025 Jun 12. doi: 10.1038/s41435-025-00338-2.
2
KLRD1 (CD94): A Prognostic Biomarker and Therapeutic Candidate in Head and Neck Squamous Cell Carcinoma.KLRD1(CD94):头颈部鳞状细胞癌的一种预后生物标志物及治疗候选靶点
J Cancer. 2025 Jan 1;16(3):982-995. doi: 10.7150/jca.104762. eCollection 2025.
3
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.
利用 HLA-G 在癌症治疗中的潜力:进展、挑战与展望。
J Transl Med. 2024 Feb 3;22(1):130. doi: 10.1186/s12967-024-04938-w.
4
Killer instincts: natural killer cells as multifactorial cancer immunotherapy.杀手本能:自然杀伤细胞作为多因素癌症免疫疗法。
Front Immunol. 2023 Nov 28;14:1269614. doi: 10.3389/fimmu.2023.1269614. eCollection 2023.
5
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.靶向 LILRB1 在癌症固有和适应性免疫检查点治疗中的研究进展。
Front Immunol. 2023 Sep 13;14:1240275. doi: 10.3389/fimmu.2023.1240275. eCollection 2023.
6
The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair.凋亡在间充质基质细胞治疗中的关键作用及其在体内平衡和正常组织修复中的意义。
Cell Mol Immunol. 2023 Jun;20(6):570-582. doi: 10.1038/s41423-023-01018-9. Epub 2023 Apr 25.
7
Vascular Protective Effects of (Rehd.) Hughes Extracts and their Mechanism in Diabetic Rats and HUVECs.(Rehd.)Hughes提取物对糖尿病大鼠和人脐静脉内皮细胞的血管保护作用及其机制
Evid Based Complement Alternat Med. 2022 Oct 19;2022:4348435. doi: 10.1155/2022/4348435. eCollection 2022.
8
Advances in the study of HLA class Ib in maternal-fetal immune tolerance.HLA Ib 类分子在母胎免疫耐受中研究进展。
Front Immunol. 2022 Aug 29;13:976289. doi: 10.3389/fimmu.2022.976289. eCollection 2022.
9
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.BND-22,一种首创的人源化 ILT2 阻断抗体,可促进抗肿瘤免疫和肿瘤消退。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-004859.
10
Innate Lymphoid Cells: Role in Immune Regulation and Cancer.固有淋巴细胞:在免疫调节和癌症中的作用。
Cancers (Basel). 2022 Apr 21;14(9):2071. doi: 10.3390/cancers14092071.